Sociodemographic and clinical profile of elderly people chronic users of omeprazole attending the basic health network.
Objective: The study's purpose has been to describe the sociodemographic and clinical profile of elderly chronic omeprazole users. Methods: This is a cross-sectional study. The participants were patients within the age group over 60 years old, who used omeprazole from the Public Pharmacy located in...
| Publicado en: | Revista de Pesquisa: Cuidado é Fundamental Vol. 11; no. 4; pp. 900 - 908 |
|---|---|
| Autores principales: | , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Revista de Pesquisa: Cuidado e Fundamental Online
Jul-Sep2019
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| Sumario: | Objective: The study's purpose has been to describe the sociodemographic and clinical profile of elderly chronic omeprazole users. Methods: This is a cross-sectional study. The participants were patients within the age group over 60 years old, who used omeprazole from the Public Pharmacy located in Panambi city, Rio Grande do Sul State. Results: A total of 60 elderly chronic omeprazole users participated in the study with an average of 67.90 ± 5.6 years old. Two serious drug interactions were identified involving citalopram and clopidogrel. It was found in some prescriptions the presence of drugs that have their absorption altered by concomitant use of omeprazole, such as captopril (25%) and enalapril (16.7%). Conclusion: Based on the findings, it is possible to highlight that this particular population is susceptible to risks that needs pharmaceutical follow-up. Objetivo: Descrever o perfil sociodemográfico e clínico de idosos usuários crônicos de omeprazol. Método: Trata-se de um estudo transversal com usuários com idade superior a 60 anos, que retiraram o omeprazol na Farmácia Pública de Panambi/RS. Resultados: Participaram da pesquisa sessenta idosos, com idade média de 67,90 ±5,6 anos. Duas interações graves foram identificadas envolvendo citalopram e clopidogrel. Observou-se a presença nas prescrições de medicamentos que tem a sua absorção alterada pelo uso concomitante com o omeprazol como captopril (25%) e enalapril (16,7%). Conclusão: Dessa forma, evidenciou-se uma população suscetível a riscos que necessita de acompanhamento farmacêutico. |
|---|